The note lists an intraday idea to buy above 484 with a target of 500 and a stoploss of 474.
Read this note →Granules India Limited
NSE GRANULES BSE 532482 INE101D01020
0 filings · 0 analysed
799.20
+45.57%
over 1 year
-
The note lists an intraday idea to buy above 484 with a target of 500 and a stoploss of 474.
-
The report forecasts Granules sales growth of 20.0% YoY and PAT growth of 36.7% YoY in 2QFY27.
-
The note lists Granules as a focus investment idea with Buy rating, CMP 836 and target 1,010.
-
The note lists Granules as a Buy with CMP Rs 875 and target Rs 1,010, implying 15% upside.
-
The report lists Granules as a stock to watch likely to show relative strength given Pharma's strong technical structure.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp. Hollow markers are broker reports, which carry a publication date but no time; they are drawn at that day's market open.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| Motilal Oswal Financial Services Ltd. (MOFSL) | 17 Sep 2026, 08:39 | long | 870.40 | 1,010.00 | 799.65 | -51% | open by 2027-09-17 |
| Motilal Oswal Financial Services Ltd. | 16 Sep 2026, 08:39 | long | 835.60 | 1,010.00 | 799.65 | -21% | open by 2027-09-16 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report forecasts Granules sales growth of 20.0% YoY and PAT growth of 36.7% YoY in 2QFY27.
Read this note →The note lists Granules as a focus investment idea with Buy rating, CMP 836 and target 1,010.
Read this note →The note lists Granules as a Buy with CMP Rs 875 and target Rs 1,010, implying 15% upside.
Read this note →The report lists Granules as a stock to watch likely to show relative strength given Pharma's strong technical structure.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief